Head to Head Contrast: Marpai (MRAI) versus Its Competitors

Marpai (NASDAQ:MRAIGet Rating) is one of 29 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its rivals? We will compare Marpai to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Marpai and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai 0 0 1 0 3.00
Marpai Competitors 67 340 555 25 2.55

Marpai currently has a consensus price target of $2.50, suggesting a potential upside of 177.78%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 66.36%. Given Marpai’s stronger consensus rating and higher possible upside, research analysts clearly believe Marpai is more favorable than its rivals.

Profitability

This table compares Marpai and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marpai -100.92% -116.50% -63.56%
Marpai Competitors -1,770.64% -69.56% -27.70%

Insider & Institutional Ownership

35.0% of Marpai shares are held by institutional investors. Comparatively, 49.9% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 41.4% of Marpai shares are held by company insiders. Comparatively, 23.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Marpai and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Marpai $14.23 million -$15.98 million -0.63
Marpai Competitors $2.07 billion $88.60 million 3.02

Marpai’s rivals have higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Marpai rivals beat Marpai on 7 of the 12 factors compared.

About Marpai

(Get Rating)

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. It also develops artificial intelligence and healthcare technology that enables the analysis of data to predict and prevent events related to diagnostic errors, hospital visits, and administrative issues. The company was incorporated in 2021 and is headquartered in New York, New York.

Receive News & Ratings for Marpai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marpai and related companies with MarketBeat.com's FREE daily email newsletter.